SPRY2 and metastatic prostate carcinoma: Genomic alterations of SPRY2 and PTEN as part of the RAS/ERK and PI3K/AKT pathways, respectively, have been detected in ∼40% of metastatic prostate cancer patients (SU2C/PCF Dream Team) (14) (Fig 1A).